The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Abstract
Learning Objectives: After completing this course, the reader will be able to: Define the historical background and biological basis of the discovery of the HER-2/neu gene and its first use as a prognostic factor in breast cancer. Recall the uses of HER-2/neu testing prior to the approval of trastuzumab including the impact on anthracycline adjuvant and first-line chemotherapy responses. Explain the basic principles of all the HER-2/neu tests in clinical practice: IHC, FISH, Southern blot, PCR, tissue ELISA, and serum ELISA. Contrast the pros and cons and uses and limitations of the IHC versus the FISH approach to HER-2/neu testing. Critique the most recent data comparing IHC with FISH for the prediction of response to single-agent trastuzumab and trastuzumab in combination with standard chemotherapy for advanced metastatic breast cancer. Describe the HER-2/neu expression patterns in all types of breast conditions, including in situ carcinoma, lobular versus ductal carcinoma, Paget's disease, male breast cancer, breast sarcomas, and benign breast disorders. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages and disadvantages of Southern blotting, polymerase chain reaction amplification, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is presented as well as its potential impact on responses to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review also evaluates the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationPrognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimaki, A. P., Sivula, A., Lundin, J. E., Lundin, M., Salminen, T. M., Haglund, C. H., Joensuu, H., & Isola, J. J. (2002) · PubMed · Cited by 780
Biology of HER2 and Its Importance in Breast Cancer
Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 737
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 622
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 611
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Self-citationHER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 554
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A., Addo, F. K., Murphy, B., Ingle, J. N., & Perez, E. A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.855 · Cited by 390
Järvinen, T. A. H., Tanner, M., Rantanen, V., Bärlund, M., Borg, Å., Grénman, S., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64952-8 · Cited by 387
Chromogenic in Situ Hybridization
Tanner, M., Gancberg, D., Di Leo, A., Larsimont, D., Rouas, G., Piccart, M. J., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64785-2 · Cited by 383
Kallioniemi, O., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., & Isola, J. J. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490504 · Cited by 346
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201222 · Cited by 332
Gullick, W., Love, S., Wright, C., Barnes, D., Gusterson, B., Harris, A., & Altman, D. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.100 · Cited by 327
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., & Bergh, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.462 · Cited by 327
Stern, D. F., Heffernan, P. A., & Weinberg, R. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.5.1729 · Cited by 327
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
Toikkanen, S., Helin, H., Isola, J., & Joensuu, H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1044 · Cited by 313
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 296
Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.15.1141 · Cited by 290
Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2
McKeage, K., & Perry, C. M. (2002) · Drugs · doi:10.2165/00003495-200262010-00008 · Cited by 289
Leo, A. D., Gancberg, D., Larsimont, D., Tanner, M., Järvinen, T. A. H., Rouas, G., Dolci, S., Leroy, J.-Y., Paesmans, M., Isola, J. J., et al. (2002) · PubMed · Cited by 267
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
Bilous, M., Dowsett, M., Hanna, W., Isola, J., Lebeau, A., Moreno, A., Penault-Llorca, F., Rüschoff, J., Tomasic, G., & van de Vijver, M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000052102.90815.82 · Cited by 264
Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1991) · PubMed · Cited by 261
Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Porta, G. D., Ménard, S., Pierotti, M. A., & Testori, A. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490109 · Cited by 259
Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical Applications
Bièche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., & Vidaud, M. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.8.1148 · Cited by 254
Lipton, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1467 · Cited by 253
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
SLAMON, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90188-5 · Cited by 243
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I., Locker, A., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237
Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome
Joshi, M., Lee, A. K. C., Loda, M. F., Camus, M. G., Pedersen, C. A., Heatley, G. J., & Hughes, K. S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960201)77:3<490::aid-cncr10>3.0.co;2-# · Cited by 233
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner, M., Järvinen, P., & Isola, J. J. (2001) · PubMed · Cited by 215
Suo, Z., Risberg, B., Kalsson, M. G., Willman, K., Tierens, A., Skovlund, E., & Nesland, J. M. (2002) · The Journal of Pathology · doi:10.1002/path.1003 · Cited by 214
Joensuu, H., Isola, J. J., Lundin, M., Salminen, T. M., Holli, K., Kataja, V. V., Pylkkänen, L. H., Turpeenniemi-Hujanen, T. M., von Smitten, K., & Lundin, J. E. (2003) · PubMed · Cited by 207
Coon, J. S., Marcus, E., Gupta-Burt, S., SEELIG, S. A., Jacobson, K., Chen, S., RENTA, V., Fronda, G., & Preisler, H. D. (2002) · PubMed · Cited by 193
Pawlowski, V., Révillion-Carette, F., Hebbar, M., Hornez, L., & Peyrat, J. (2000) · PubMed · Cited by 187
Wang, S., Saboorian, M. H., Frenkel, E., Hynan, L., Gokaslan, S. T., & Ashfaq, R. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.5.374 · Cited by 180
Thor, A. D., Liu, S., Edgerton, S., Moore, D., Kasowitz, K. M., Benz, C. C., Stern, D. F., & DiGiovanna, M. P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.18.3230 · Cited by 175
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
Dowsett, M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080191 · Cited by 171
Zhao, J., Wu, R., Au, A., Marquez, A., Yu, Y., & Shi, Z. (2002) · Modern Pathology · doi:10.1038/modpathol.3880582 · Cited by 160
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
The Predictive Value of HER2 in Breast Cancer
Piccart, M. J., Lohrisch, C. A., Leo, A. D., & Larsimont, D. (2001) · Oncology · doi:10.1159/000055405 · Cited by 155
Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer
Spizzo, G., Obrist, P., Ensinger, C., Theurl, I., Dünser, M., Ramoni, A., Gunsilius, E., Eibl, G., Mikuz, G., & Gastl, G. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10270 · Cited by 152
Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Watanabe, S., Terada, M., & Yamamoto, H. (1990) · Cancer · Cited by 151
Molecular markers in male breast carcinoma
Rayson, D., Erlichman, C., Suman, V. J., Roche, P. C., Wold, L. E., Ingle, J. N., & Donohue, J. H. (1998) · Cancer · Cited by 150
Ménard, S., Valagussa, P., Pilotti, S., Gianni, L., Biganzoli, E. M., Boracchi, P., Tomasic, G., Casalini, P., Marubini, E., COLNAGHI, M. I., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.329 · Cited by 149
c-erbB-2 in breast cancer: Development of a clinically useful marker
Hayes, D. F., & Thor, A. D. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.32899 · Cited by 147
Increased HER2 With U.S. Food and Drug Administration-Approved Antibody
Roche, P. C., & Ingle, J. N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.434 · Cited by 147
Wang, S., Saboorian, M. H., Frenkel, E. P., Haley, B., Siddiqui, M. T., Gokaslan, S. T., Wians, F. H., Hynan, L. S., & Ashfaq, R. (2001) · American Journal of Clinical Pathology · doi:10.1309/tmuw-g4wb-lxj2-fudn · Cited by 137
Status of HER-2 in male and female breast carcinoma
Bloom, K. J., Govil, H., Gattuso, P., Reddy, V., & Francescatti, D. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00733-4 · Cited by 134
Self-citationThe relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
O'Reilly, S., Barnes, D. M., Camplejohn, R., Bártková, J., Gregory, W. M., & Richards, M. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.102 · Cited by 130
Vincent‐Salomon, A., Jouve, M., Génin, P., Fréneaux, P., Sigal‐Zafrani, B., Caly, M., Beuzeboc, P., Pouillart, P., & Sastre‐Garau, X. (2002) · Cancer · doi:10.1002/cncr.10456 · Cited by 115
Leo, A. D., Larsimont, D., Gancberg, D., Järvinen, T. A. H., Beauduin, M., Vindevoghel, A., Michel, J., Focan, C., Ries, F., Gobert, P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011669223035 · Cited by 107
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer
Hortobágyi, G. N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90108-3 · Cited by 105
Prognostic relevance of altered Fas (CD95)-system in human breast cancer
Mottolese, M., Buglioni, S., Bracalenti, C., Cardarelli, M. A., Ciabocco, L., Giannarelli, D., Botti, C., Natali, P. G., Concetti, A., & Venanzi, F. M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000320)89:2<198::aid-ijc16>3.0.co;2-l · Cited by 105
Prognostic and predictive value of HER2/neu oncogene in breast cancer
Masood, S., & Bui, M. M. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10181 · Cited by 101
Harris, L. N., Liotcheva, V. B., Broadwater, G., Ramirez, M. J., Maimonis, P. J., Anderson, S., Everett, T., Harpole, D. H., Moore, M. B., Berry, D. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1698 · Cited by 96
Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions
Symmans, W. F., Liu, J., Knowles, D. M., & Inghirami, G. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90039-x · Cited by 93
Self-citationMolecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53
Beenken, S. W., Grizzle, W. E., Crowe, D. R., Conner, M., Weiss, H. L., Sellers, M. T., Krontiras, H., Urist, M. M., & Bland, K. I. (2001) · Annals of Surgery · doi:10.1097/00000658-200105000-00006 · Cited by 93
Giai, M., Roagna, R., Ponzone, R., Bortoli, M. D., Dati, C., & Sismondi, P. (1994) · PubMed · Cited by 89
Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs, M., Hacène, K., Bouchet, C., Doussal, V. L., Tubiana-Hulin, M., & Spyratos, F. (2000) · PubMed · Cited by 85
Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay
Eppenberger‐Castori, S., Kueng, W., Benz, C. C., Caduff, R. F., Varga, Z., Bannwart, F., Fink, D., Dieterich, H., Höhl, M., Müller, H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.645 · Cited by 81
DiGiovanna, M. P., & Stern, D. F. (1995) · PubMed · Cited by 81
Mack, L. A., Kerkvliet, N. I., Doig, G. S., & O’Malley, F. P. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90014-9 · Cited by 77
Current Status of HER2 Testing
Schnitt, S. J., & Jacobs, T. W. (2001) · American Journal of Clinical Pathology · doi:10.1309/wmn8-vtr5-dugf-x12l · Cited by 76
Harris, L. N., Yang, L., Liotcheva, V. B., Pauli, S., Iglehart, J. D., Colvin, O. M., & Hsieh, T. S. (2001) · PubMed · Cited by 75
Engineered antibodies take center stage
Huston, J. S., & George, A. J. T. (2001) · Human Antibodies · doi:10.3233/hab-2001-103-405 · Cited by 73
Prognostic value of c‐erbB2 expression in breast cancer
Tsutsui, S., Ohno, S., Murakami, S., Hachitanda, Y., & Oda, S. (2002) · Journal of Surgical Oncology · doi:10.1002/jso.10079 · Cited by 73
Mehta, R., McDermott, J. H., Hieken, T. J., Marler, K. C., Patel, M. K., Wild, L., & Gupta, T. K. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2409 · Cited by 64
The Association of HER-2/neu Amplification With Breast Cancer Recurrence
Carr, J. A. (2000) · Archives of Surgery · doi:10.1001/archsurg.135.12.1469 · Cited by 63
Yu, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90277-5 · Cited by 62
Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
Jacquemier, J. D., Penault-Llorca, F. M., Viens, P., Houvenaeghel, G. F., Hassoun, J., Torrente, M., Adélaı̈de, J., & Birnbaum, D. (1994) · PubMed · Cited by 44
Shpitz, B., Bomstein, Y., Sternberg, A., Klein, E. S., Liverant, S., Groisman, G. M., & Bernheim, J. (2000) · Journal of Surgical Oncology · Cited by 42
Rudolph, P., Alm, P., Olsson, H. L., Heidebrecht, H.-J., Fernö, M., Baldetorp, B., & Parwaresch, R. M. (2001) · Human Pathology · doi:10.1053/hupa.2001.22748 · Cited by 41
The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (Review)
Kim, R., Tanabe, K., Uchida, Y., Osaki, A., & Toge, T. (2002) · Oncology Reports · doi:10.3892/or.9.1.3 · Cited by 40
Charpin, C., Garcia, S., Bouvier, C., Martini, F., Lavaut, M.-N., Allasia, C., Bonnier, P., & Andrac, L. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.283 · Cited by 36
Yaziji, H., & Gown, A. M. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200211000-00002 · Cited by 32
Pawlowski, Révillion, F., Hornez, L., et al. (2000) · PubMed · Cited by 31
El-Ahmady, O., El-Salahy, E. M., Mahmoud, M., Wahab, M. A., Eissa, S., & Khalifa, A. (2002) · PubMed · Cited by 24
Cited by
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Yersal, O. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.412 · Cited by 1,156
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Metadata
- Authors
- Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-01
- Volume
- 8
- Issue
- 4
- Pages
- 307-325
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2117115931
- Cited by
- 610
- References
- 103
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.